Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q1 FY27 Earnings Presentation
22 slides from Metropolis Healthcare's earnings presentation, Aug 4, 2026
Slide 1: Exchange filing cover letter for investor presentation
Ref: MHL/Sec&Legal/2026-27/33 August 04, 2026 To, BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are
Slide 2: Q1 FY27 Investor Presentation
Q1 FY27 Investor Presentation 1
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been Certain matters discussed in this Presentation may contain statements regarding the prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely Company’s market opportunity and bu
Slide 4: Metropolis - diagnostics that's trusted by doctors and patients alike
Metropolis - diagnostics that’s trusted by doctors and patients alike 209 35 2 OUR VISION Clinical Labs ISO:15189 Accredited CAP Accredited Labs Labs 31 India / 4 Kenya India OUR BRAND PROMISE 45 + 4,500 + 5,000 + Years of credible Tests & Profiles Service Network CAGR revenue growth over experience
Slide 5: Key Financial Highlights
Q1 FY27 Key Financial Highlights REVENUE EBITDA PAT INR 450 Cr INR 113 Cr INR 57 Cr 17% YoY 27% YoY 26% YoY NETWORK EBITDA MARGIN PAT MARGIN 5,003 25.2% 12.6% 8% YoY 210 bps 90 bps ● Mid - teen revenue growth delivered despite no ● Q1FY27 EBITDA grew by 210 bps driven by ● Sustained demand momentum
Slide 6: Key Performance Indicators
Q1 FY27 Key Performance Indicators B2C REVENUE B2B REVENUE TRUHEALTH INR 257 Cr INR 193 Cr INR 81 Cr 18% YoY 15% YoY 22% YoY PATIENT VOLUME TEST VOLUME SPECIALTY 3.7 Mn 7.8 Mn INR 178 Cr 10% YoY 11% YoY 17% YoY ● Double - digit patient and test volume growth , ● 17% growth in specialty testing reven
Slide 7: Consistently delivering patient & test volume growth
Q1 FY27 Consistently delivering patient & test volume growth Patient Volume Test Volume Revenue Per Patient Revenue Per Test Q1FY27 Segment Q1FY27 Segment (in Mn) (in Mn) (INR) (INR) Contribution Revenue Growth 3.69 7.83 1,219 575 1,151 546 3.35 7.07 TruHealth 22% Specialty 17% Semi - Special 15% Sp
Slide 8: B2C revenue up 18% YoY & B2B revenue up 15% YoY
Q1 FY27 · CHANNEL MIX B2C revenue up 18% YoY & B2B revenue up 15% YoY B2C · 57% B2B · 43% B2C +18% YoY B2B +15% YoY Own, franchisee & rural centres B2B labs, hospitals, government, corporate & clinical trials TruHealth Growth Specialty Growth TruHealth Growth Specialty Growth +22% +21% +23% +15% • M
Slide 9: TruHealth & Speciality
Q1 FY27 REVENUE GROWTH TruHealth & Speciality TruHealth Speciality Strong revenue momentum, premium mix & digital acceleration GROWTH CONTRIBUTION GROWTH CONTRIBUTION 22% 18% 17% 40% ● Radiology - integrated wellness packages ● grew 40%+ through range optimisation and focused upselling. ● Premium Tr
Slide 10: Diversified revenue contribution across geographies
Q1 FY27 · REACH Diversified revenue contribution across geographies By Region By City Tier ~750 West 50% Tier I 67% South 27% Tier II 7% North 18% Tier III 26% East 6% ~25% Region Growth Tier Growth West 14% Tier I 11% South 14% Tier II 14% 18% North 19% Tier III 25% North India contribution, up fro
Slide 11: Building a scalable, efficient network
INFRASTRUCTURE Building a scalable, efficient network Laboratory Network Service Network 5,026 5,003 4,536 210 212 209 4,150 199 3,675 175 161 3,134 125 2,555 FY21 FY22 FY23 FY24 FY25 FY26 Q1FY27 FY21 FY22 FY23 FY24 FY25 FY26 Q1FY27 Over the last 5 years 87 labs added to the network. In Q1FY27, Over
Slide 12: Consolidated Profit & Loss Statement
Q1 FY27 Consolidated Profit & Loss Statement Profit & Loss Statement Q1FY27 Q1FY26 Y - o- Y Revenue from Operations 450.2 386.1 16.6% Total Cost 337.0 296.9 EBITDA 113.2 89.1 27.1% EBITDA Margin (%) 25.2% 23.1% 210 bps Depreciation 32.4 30.8 Other Income 5.1 7.5 EBIT 86.0 65.8 30.6% Finance Cost 8.3
Slide 13: Metropolis 3.0
STRATEGY Metropolis 3.0 The next phase of profitable, science-led growth — strengthening the core, expanding into adjacencies, and building lasting shareholder value.
Slide 14: The Indian diagnostics industry
MARKET CONTEXT The Indian diagnostics industry Market size — US$ bn (~11% CAGR to 2034E) 28.5 ~US$11 bn ~11% 21.0 India diagnostic labs market size, 2025 Projected CAGR, 2025 –2034E 15.1 11.0 ~15% >60% 2025 2028E 2031E 2034E Organised chains’ share — rest is Share of mortality from non - fragmented
Slide 15: Key pillars of the strategy - poised to grow further
METROPOLIS 3.0 Key pillars of the strategy - poised to grow further 1 2 Leading with Technology Differentiate Scientifically Pioneer AI and digital innovation to Lead with scientific excellence and redefine diagnostics and elevate uncompromising diagnostic quality, customer experience, building on o
Slide 16: Driving business growth through digital transformation
TECHNOLOGY Driving business growth through digital transformation THE TECHNOLOGY STACK A UNIQUE HEALTHCARE TECHNOLOGY STACK DELIVERS Enhanced Productivity Second - generation Point of Sale platform — Registration & Invoicing Platform 2.0. Efficient Patient Personalization Registration Rapid Scalabil
Slide 17: Scientifically driven, with a strong focus on quality
SCIENCE · RESEARCH · ACADEMICS Scientifically driven, with a strong focus on quality 36 347 99% 99.99% 100% new tests added in Q1FY27 tests added in FY26 including EQAS external quality report accuracy labs under CAP / NABL / (incl. CDP) integrating Core menu assurance score KENAS or benchmarked Sci
Slide 18: Metropolis ESG goals & key plans
SUSTAINABILITY Metropolis ESG goals & key plans E Emissions for a greener tomorrow S Quality, safety, diversity & well - being G Integrity, security & compliance Carbon neutrality by 2043 · 45% lower emissions intensity & B2C NPS @ 90 by 2028 · 100% OHS awareness & training · Zero data breaches · pa
Slide 19: CSR at Metropolis — creating a positive impact
CORPORATE SOCIAL RESPONSIBILITY CSR at Metropolis — creating a positive impact ADOLESCENT REPRODUCTIVE MEDENGAGE PREVENTIVE HEALTHCARE SEXUAL HEALTH (ARSH) Preventive Healthcare Empowering Adolescents with Health and Life Nurturing young medical talent Strengthening Community Health Skills • 1.3 lak
Slide 20: A dynamic leadership team for the next level of growth
‘PROMOTER LED — PROFESSIONALLY DRIVEN’ A dynamic leadership team for the next level of growth Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Founder & Non – Executive Promoter & Executive Chairperson Managing Director Non - Independent Director Dynamic Leadership Team for Next Level of Growth Sa
Slide 21: Recent awards & accolades
RECOGNITION Recent awards & accolades Jul’26 Jul’26 Jun’26 Best Diagnostic Chain of the Year 2026, FE Gold, Best Social Impact in Healthcare Best Healthcare Brands Award, ET Edge, Healthcare Excellence Awards. 2026, FE Healthcare Excellence Awards. 2026 May’26 Excellence in Laboratory Quality Award
Slide 22: For further information, please contact
METROPOLIS For further information, please contact COMPANY INVESTOR RELATIONS ADVISORS Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. Mr. Kamlesh Kulkarni Mr. Sagar Shroff / Mr. Shogun Jain 20
Metropolis Healthcare — Q1 FY27 Earnings Presentation on 6ix